Home › Trials › NCT06818643

Evaluating MK-3120 for advanced solid tumors

A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors

PHASE1; PHASE2 · Merck Sharp & Dohme LLC · NCT06818643

This study is testing a new treatment called MK-3120 to see if it can help people with advanced solid tumors that can't be removed by surgery.

Quick facts

PhasePHASE1; PHASE2
Study typeInterventional
Enrollment270 (estimated)
Ages18 Years and up
SexAll
SponsorMerck Sharp & Dohme LLC (industry)
Locations45 sites (Birmingham, Alabama and 44 other locations)
Trial IDNCT06818643 on ClinicalTrials.gov

What this trial studies

This study aims to assess the safety and efficacy of MK-3120 in participants with advanced solid tumors that are unresectable or metastatic. The research focuses on individuals whose cancer has spread and cannot be surgically removed. Participants will undergo treatment with MK-3120, and the study will monitor their tolerance and any adverse effects. The goal is to gather data that could lead to new treatment options for these patients.

Who should consider this trial

Good fit: Ideal candidates include individuals with confirmed advanced solid tumors that are unresectable or metastatic and who meet specific health criteria.

Not a fit: Patients with solid tumors that are resectable or those who do not meet the eligibility criteria may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a new treatment option for patients with advanced solid tumors.

How similar studies have performed: Other studies have explored similar treatments for advanced solid tumors, but the specific approach with MK-3120 is novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Has a confirmed advanced (unresectable and/or metastatic) solid tumor and has received or been intolerant to all available treatments
* If human immunodeficiency virus (HIV) positive, has well controlled HIV on antiretroviral therapy (ART)
* If hepatitis B surface antigen (HBsAg) positive, must have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
* If hepatitis C virus (HCV) infected, must have undetectable HCV viral load

Exclusion Criteria:

* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
* Has uncontrolled significant cardiovascular disease or cerebrovascular disease
* Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
* Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or require repeated drainage
* Is HIV-positive and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
* Known additional malignancy that is progressing or has required active treatment within the past 2 years
* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
* Active infection requiring systemic therapy, with exceptions
* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
* Has HBV or HCV infection

Where this trial is running

Birmingham, Alabama and 44 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Advanced Solid Tumors, Malignant Neoplasm

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.